
|Articles|July 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 7
- Volume 15
- Issue 7
Genentech Seeks Expanded Use of Avastin in Breast Cancer
Genentech Seeks Expanded Use of Avastin in Breast Cancer
Advertisement
SAN FRANCISCO, CalifGenentech has submitted an application to the FDA for expanded use of bevacizumab (Avastin) in combination with taxane chemotherapy for treatment of chemotherapy-naïve recurrent or metastatic breast cancer. Phase III data showed that patients who received bevacizumab in combination with paclitaxel had a 52% reduction in risk of disease progression or death, compared to those who received paclitaxel alone.
Articles in this issue
about 20 years ago
High-Quality Screening Colonoscopy Priority for GI Docsabout 20 years ago
Denosumab Suppresses Bone Resorption in Breast Ca Metsabout 20 years ago
FDA Approves Priority Review of Merck's Zolinza (Vorinostat)about 20 years ago
FDA Approves Revlimid for Myeloma Rxabout 20 years ago
Real-Time RT Planning, Delivery in the Bronxabout 20 years ago
Phase III Trial of Enzastaurin for NHL Patients Initiatedabout 20 years ago
Racial Disparities in Prostate Ca Recurrenceabout 20 years ago
HNPCC Pts May Reject Prophylactic Subtotal ColectomyAdvertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
177Lu-Edoterotide Handed CRL by FDA For GEP-NETs Treatment
2
BI-1808 Earns FDA Fast Track Status for Advanced Ovarian Cancer
3
Does Patient Selection Inflate CAR T Outcomes in Multiple Myeloma?
4
Bispecific Antibodies for Older Patients With Relapsed/Refractory Multiple Myeloma
5

























































